Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 10 | 2026 | 313 | 1.250 |
Why?
|
| Glioma | 6 | 2026 | 122 | 0.980 |
Why?
|
| Neurocutaneous Syndromes | 2 | 2022 | 6 | 0.770 |
Why?
|
| Child, Preschool | 17 | 2025 | 1174 | 0.610 |
Why?
|
| Stress, Psychological | 4 | 2016 | 233 | 0.600 |
Why?
|
| Lipomatosis | 1 | 2018 | 2 | 0.590 |
Why?
|
| Neoplasms | 6 | 2016 | 874 | 0.580 |
Why?
|
| Eye Diseases | 1 | 2018 | 31 | 0.570 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 433 | 0.530 |
Why?
|
| Child | 18 | 2026 | 2292 | 0.470 |
Why?
|
| Adaptation, Psychological | 2 | 2013 | 123 | 0.450 |
Why?
|
| Mothers | 2 | 2013 | 124 | 0.440 |
Why?
|
| Histones | 3 | 2026 | 96 | 0.430 |
Why?
|
| Psychotherapy | 1 | 2012 | 16 | 0.380 |
Why?
|
| Astrocytoma | 2 | 2025 | 37 | 0.370 |
Why?
|
| Adolescent | 13 | 2026 | 3198 | 0.340 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2008 | 30 | 0.270 |
Why?
|
| Humans | 26 | 2026 | 28896 | 0.260 |
Why?
|
| Brain Stem Neoplasms | 2 | 2020 | 12 | 0.260 |
Why?
|
| Thrombosis | 1 | 2008 | 150 | 0.240 |
Why?
|
| Female | 19 | 2026 | 15646 | 0.240 |
Why?
|
| DNA Modification Methylases | 1 | 2026 | 14 | 0.240 |
Why?
|
| DNA Repair Enzymes | 1 | 2026 | 10 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2026 | 22 | 0.240 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2026 | 51 | 0.240 |
Why?
|
| Receptor, trkB | 1 | 2025 | 9 | 0.240 |
Why?
|
| Antineoplastic Agents | 2 | 2025 | 686 | 0.230 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2025 | 16 | 0.230 |
Why?
|
| Male | 15 | 2026 | 13943 | 0.230 |
Why?
|
| Pyrazoles | 1 | 2025 | 79 | 0.220 |
Why?
|
| Parents | 2 | 2016 | 133 | 0.220 |
Why?
|
| Pyrimidines | 1 | 2025 | 128 | 0.220 |
Why?
|
| Medulloblastoma | 2 | 2016 | 20 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2025 | 166 | 0.210 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2015 | 10 | 0.210 |
Why?
|
| Camptothecin | 4 | 2016 | 16 | 0.210 |
Why?
|
| Young Adult | 7 | 2025 | 2839 | 0.210 |
Why?
|
| Treatment Outcome | 4 | 2026 | 2426 | 0.210 |
Why?
|
| Infant | 6 | 2025 | 1026 | 0.200 |
Why?
|
| Parent-Child Relations | 2 | 2016 | 73 | 0.200 |
Why?
|
| Tuberous Sclerosis | 1 | 2022 | 3 | 0.190 |
Why?
|
| Neurofibromatosis 1 | 1 | 2022 | 6 | 0.190 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2022 | 9 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2021 | 12 | 0.170 |
Why?
|
| Mercaptopurine | 1 | 2020 | 1 | 0.170 |
Why?
|
| Directly Observed Therapy | 1 | 2020 | 1 | 0.170 |
Why?
|
| Supratentorial Neoplasms | 1 | 2020 | 4 | 0.160 |
Why?
|
| Text Messaging | 1 | 2020 | 23 | 0.160 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 43 | 0.160 |
Why?
|
| Medication Adherence | 1 | 2020 | 48 | 0.160 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 50 | 0.160 |
Why?
|
| Quality of Life | 2 | 2016 | 521 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2018 | 16 | 0.150 |
Why?
|
| N-Terminal Acetyltransferase A | 1 | 2018 | 1 | 0.140 |
Why?
|
| N-Terminal Acetyltransferase E | 1 | 2018 | 1 | 0.140 |
Why?
|
| Pyridones | 1 | 2018 | 36 | 0.140 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 15 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 88 | 0.140 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 16 | 0.140 |
Why?
|
| Intellectual Disability | 1 | 2018 | 16 | 0.140 |
Why?
|
| Dacarbazine | 3 | 2016 | 15 | 0.140 |
Why?
|
| Mutation | 4 | 2026 | 867 | 0.140 |
Why?
|
| Disease Progression | 1 | 2018 | 477 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 841 | 0.120 |
Why?
|
| Prognosis | 3 | 2026 | 811 | 0.120 |
Why?
|
| Adult | 7 | 2022 | 8035 | 0.120 |
Why?
|
| Phenotype | 1 | 2018 | 686 | 0.120 |
Why?
|
| Hematoma, Subdural, Chronic | 1 | 2015 | 8 | 0.120 |
Why?
|
| Cerebellar Neoplasms | 1 | 2016 | 30 | 0.120 |
Why?
|
| Uncertainty | 1 | 2015 | 25 | 0.120 |
Why?
|
| Benzenesulfonates | 1 | 2015 | 18 | 0.120 |
Why?
|
| Imines | 1 | 2015 | 21 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 31 | 0.120 |
Why?
|
| Sarcoma | 1 | 2015 | 29 | 0.110 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 15 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 71 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2015 | 109 | 0.110 |
Why?
|
| Child Behavior Disorders | 1 | 2013 | 25 | 0.100 |
Why?
|
| Pons | 1 | 2012 | 7 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Retinoblastoma | 1 | 2012 | 8 | 0.100 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 23 | 0.100 |
Why?
|
| Retinal Neoplasms | 1 | 2012 | 8 | 0.100 |
Why?
|
| Metalloporphyrins | 1 | 2012 | 18 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2012 | 33 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2012 | 34 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 31 | 0.090 |
Why?
|
| Bevacizumab | 3 | 2020 | 106 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2012 | 222 | 0.090 |
Why?
|
| Middle Aged | 5 | 2015 | 7416 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2012 | 464 | 0.080 |
Why?
|
| Vincristine | 1 | 2010 | 9 | 0.080 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 34 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2026 | 2635 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 32 | 0.080 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2008 | 27 | 0.070 |
Why?
|
| Thrombophilia | 1 | 2008 | 10 | 0.070 |
Why?
|
| Diarrhea | 1 | 2008 | 57 | 0.070 |
Why?
|
| Hemostasis | 1 | 2008 | 48 | 0.070 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 54 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 432 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 303 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2025 | 25 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2025 | 149 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1032 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2015 | 75 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 347 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 224 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2021 | 25 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 65 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 194 | 0.040 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 48 | 0.040 |
Why?
|
| Valproic Acid | 1 | 2020 | 15 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 91 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 285 | 0.040 |
Why?
|
| Enzyme Stability | 1 | 2018 | 31 | 0.040 |
Why?
|
| Syndrome | 1 | 2018 | 79 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2018 | 212 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 667 | 0.030 |
Why?
|
| Decorin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Sulfatases | 1 | 2015 | 6 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2015 | 60 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2015 | 31 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 314 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 332 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 465 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2013 | 17 | 0.020 |
Why?
|
| Lymphopenia | 1 | 2012 | 8 | 0.020 |
Why?
|
| Retinoblastoma Protein | 1 | 2012 | 10 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 100 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 102 | 0.020 |
Why?
|
| Karyotyping | 1 | 2012 | 25 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2012 | 31 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2013 | 89 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 236 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 825 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 326 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 151 | 0.020 |
Why?
|
| Medical Audit | 1 | 2010 | 15 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2010 | 48 | 0.020 |
Why?
|
| Hypertension | 1 | 2012 | 309 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 471 | 0.020 |
Why?
|
| Health Status | 1 | 2010 | 149 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2015 | 1469 | 0.020 |
Why?
|
| Cephalosporins | 1 | 2008 | 18 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 1002 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 4809 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 676 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 10703 | 0.010 |
Why?
|